drugset / Trial / NCT04065737
Sintilimab to Prevent High-risk Oral Premalignant Lesions Cancerization
Phase 2
Unknown
29 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelPrevention
Summary
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate how well sintilimab works in preventing high-risk oral premalignant lesions cancerization.
Timeline
- Start
- 2019-08-15
- Primary completion
- 2022-07-15
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Other |